MNMD,Mind Medicine (MindMed) Inc. | Healthcare

Healthcare

MNMD

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Mind Medicine (MindMed) Inc.MNMD

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder.

The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

The company is headquartered in New York, New York.

Latest News >

Safran posts higher Q1 revenue, keeps financial targets

Apr 25, 2024

PARIS, April 26 (Reuters) - French jet engine maker Safran posted an 18.1% year-on-year increase in first-quarter revenue and reaffirmed financial targets for the year, while joining its U.S. partner GE Aerospace in lowering a target for engine deliveries. The Paris-based company posted quarterly revenues of 6.22 billion euros ($6.67 billion), up by 19.1% on an underlying basis. The widely...

Amundi's Q1 inflows beat expectations on Asian JV contribution

Apr 25, 2024

PARIS (Reuters) - Amundi, Europe's biggest fund manager, posted better-than-expected first-quarter inflows on Friday thanks to its joint ventures in Asia and continued appetite for risk-averse products that underpinned 9.4% yearly growth of assets under management. Total AUM at Amundi rose by close to 17 billion euros ($18.23 billion) in the quarter to 2,116 billion euros, setting a new record and...

Beijing auto show: Themes and highlights

Apr 25, 2024

BEIJING, April 26 (Reuters) - China's largest auto show opened in Beijing with the biggest names showing off their latest electric vehicles (EVs), underlining how the world's largest auto market is already in an all-electric state of mind, and isn't looking back. Here are the main takeaways: OVERCAPACITY & GEOPOLITICS The last thing China needs is more electric cars crowding...

Research Alert: CFRA Keeps Sell Opinion On Shares Of Graco Inc.

Apr 25, 2024

12:55 AM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target of $76, applying a forward P/E multiple of 24x our 2025 EPS forecast of $3.15 (trimmed from $3.18; 2024 EPS reduced by $0.06 to $3.04),...